Sickly Healthcare Stocks Are Perking Up. For Contrarian Investors, Buying Now Could Be Just the Remedy to Protect Your Portfolio.

When macro volatility ticks up and tech momentum begins to feel fragile, the Health Care Select Sector SPDR Fund (XLV) is routinely prescribed as the ultimate defensive remedy. This time around, XLV seems like an especially effective treatment for portfolio maladies. This daily chart is encouraging to me. Thatโ€™s a very promising percentage price oscillator…


Sickly Healthcare Stocks Are Perking Up. For Contrarian Investors, Buying Now Could Be Just the Remedy to Protect Your Portfolio.

When macro volatility ticks up and tech momentum begins to feel fragile, the Health Care Select Sector SPDR Fund (XLV) is routinely prescribed as the ultimate defensive remedy. This time around, XLV seems like an especially effective treatment for portfolio maladies.

This daily chart is encouraging to me. Thatโ€™s a very promising percentage price oscillator (PPO) indicator, even if the moving averages have yet to turn up meaningfully.

More News from Barchart

www.barchart.com
www.barchart.com

This is one of the 11 sectors of the S&P 500 Index ($SPX), and the ETF holds all the healthcare stocks within the index, with weightings to each stock based on its market capitalization. Healthcare was once a leading S&P 500 sector. Now, it ranks sixth.

The mighty have fallen. But they might just get back up.

Healthcare provides a multitrillion-dollar cushion of inelastic demand. In other words, people need medical treatment regardless of where interest rates go or how a single chipmakerโ€™s earnings shake out. That does not mean it should be the biggest sector any time soon. However, it does mean that when it sells at under 18x trailing earnings, it is worth a look. Especially with the technicals rounding into shape.

www.barchart.com
www.barchart.com

XLV has about 60 holdings. However, in classic 2026 fashion, just 10 of them account for 60% of the assets. Thatโ€™s because over time, a few drug makers, healthcare providers, and medical device makers have come to dominate. And thatโ€™s where the current case gets interesting.

Why XLV Is an Interesting Contrarian Play Right Now

However, looking at XLV solely as a monolithic safety trade masks a massive fundamental divergence occurring beneath the surface. To truly understand where the risks and rewards lie for the rest of the year, we have to look past the core ticker and dissect the three critical subsegments powering the sector: medical devices, health insurance, and pure pharmaceuticals.

Medical devices function as the high-beta, growth-oriented engine of the healthcare universe. The segment is heavily driven by procedure volumes, technological milestones, and capital expenditure budgets at major hospitals. Now, with interest rates stuck in a higher-for-longer regime, capital-intensive med-tech firms are facing compressed margins.

Source link